Cargando…

Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study

BACKGROUND: To mitigate a national shortage of WIBP-CorV COVID-19 vaccine, China’s regulator approved administering BBIBP-CorV after WIBP-CorV for completion of a primary series. In a pragmatic observational study, we compared immunogenicity and safety of a primary series of WIBP-CorV followed by BB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaoqi, Deng, Yao, Zhao, Li, Wang, Lei, Fu, Zhenwang, Tang, Lin, Ye, Fei, Liu, Qianqian, Wang, Wenling, Wang, Siquan, Hu, Bo, Guan, Xuhua, Han, Zhuling, Tong, Yeqing, Rodewald, Lance E., Yin, Zundong, Tan, Wenjie, Wang, Fuzhen, Huang, Baoying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393163/ https://www.ncbi.nlm.nih.gov/pubmed/36031501 http://dx.doi.org/10.1016/j.vaccine.2022.08.037

Ejemplares similares

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination
por: Wang, Fuzhen, et al.
Publicado: (2022)

Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Wang, Fuzhen, et al.
Publicado: (2021)

Vaccination strategy and challenges for consolidating successful containment of covid-19 with population immunity in China
por: An, Zhijie, et al.
Publicado: (2021)

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
por: Wang, Yamin, et al.
Publicado: (2021)

“If the world doesn’t share the vaccine, the virus will take on the world”
por: Yin, Zundong, et al.
Publicado: (2021)

Vaccinate with Confidence and Finish Strong
por: Rodewald, Lance, et al.
Publicado: (2022)

Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection
por: Wang, Fuzhen, et al.
Publicado: (2023)

Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
por: Xu, Shiyao, et al.
Publicado: (2023)

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study
por: Tang, Lin, et al.
Publicado: (2022)

Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022
por: Li, Mingshuang, et al.
Publicado: (2022)

Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021
por: Ma, Chao, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Prioritization of Vaccines for Inclusion into China’s Expanded Program on Immunization: Evidence from Experts’ Knowledge and Opinions
por: Ma, Chao, et al.
Publicado: (2022)

Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats
por: Wang, Wenling, et al.
Publicado: (2019)

Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

Vaccination Guidelines During and After the COVID-19 Epidemic in China
por: Yu, Wenzhou, et al.
Publicado: (2020)

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
por: Wu, Dan, et al.
Publicado: (2022)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
por: Li, Juan, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021)

Effectiveness of Inactivated COVID-19 Vaccines against Delta-Variant COVID-19: Evidence from an Outbreak in Inner Mongolia Autonomous Region, China
por: Ma, Chao, et al.
Publicado: (2023)

Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial
por: Li, Yan, et al.
Publicado: (2021)

Effectiveness of Catch-Up Vaccinations after COVID-19 Containment — China, 2020
por: Wu, Jing, et al.
Publicado: (2020)

Senior Research Scholars in China CDC’s National Immunization Program
por: Wang, Miao, et al.
Publicado: (2021)

Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus
por: Lan, Jiaming, et al.
Publicado: (2018)

Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice
por: Zhao, Fu-jie, et al.
Publicado: (2022)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice
por: Mao, Qunying, et al.
Publicado: (2012)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Exporting China’s Successes in Vaccine Preventable Hepatitis
por: Rodewald, Lance E.
Publicado: (2020)

Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
por: Wang, Wenjun, et al.
Publicado: (2021)

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
por: Zhou, Jun, et al.
Publicado: (2005)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
por: Qin, Ede, et al.
Publicado: (2006)

Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021
por: Yang, Hong, et al.
Publicado: (2023)

Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes
por: Fu, Yang, et al.
Publicado: (2022)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
por: Nurpeisova, Ainur, et al.
Publicado: (2022)

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
por: Yang, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pjehhqns135rmjudimrtkdlp9j